1 reports of this reaction
1.9% of all APIS MELLIFERA reports
#9 most reported adverse reaction
ANAPHYLACTIC REACTION is the #9 most commonly reported adverse reaction for APIS MELLIFERA, manufactured by Boiron. There are 1 FDA adverse event reports linking APIS MELLIFERA to ANAPHYLACTIC REACTION. This represents approximately 1.9% of all 52 adverse event reports for this drug.
Patients taking APIS MELLIFERA who experience anaphylactic reaction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAPHYLACTIC REACTION is a less commonly reported adverse event for APIS MELLIFERA, but still significant enough to appear in the safety profile.
In addition to anaphylactic reaction, the following adverse reactions have been reported for APIS MELLIFERA:
The following drugs have also been linked to anaphylactic reaction in FDA adverse event reports:
ANAPHYLACTIC REACTION has been reported as an adverse event in 1 FDA reports for APIS MELLIFERA. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAPHYLACTIC REACTION accounts for approximately 1.9% of all adverse event reports for APIS MELLIFERA, making it a notable side effect.
If you experience anaphylactic reaction while taking APIS MELLIFERA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.